Jay Lalezari, CEO, CytoDyn, emphasizes how regulatory T cells play a crucial role in tumor progression by enabling cancers to evade immune detection.
Jay Lalezari, PhD
Advertisement
Articles by Jay Lalezari, PhD
Jay Lalezari, CEO of CytoDyn, explains how the CCR5 receptor has emerged as a pivotal target in metastatic cancers due to its dual role in promoting tumor cell migration and shaping a protective tumor microenvironment.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Report: Richard Pazdur Out as Director of CDER
2
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
3
Regeneron Announces $150 Million Collaboration with Tessera Therapeutics to Develop Gene Editing Therapy
4
Reshaping Kidney Care: Q&A with Stylianos Sarrigiannidis
5
